866-997-4948(US-Canada Toll Free)

KW-6002 Analysis and Forecasts from 2013 to 2020

Published By :

GlobalData

Published Date : Jul 2011

Category :

Therapeutic Area

No. of Pages : 25 Pages


GlobalDatas pharmaceuticals report, KW-6002 Analysis and Forecasts from 2013 to 2020 provides KW-6002 sales estimates for Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2013-2020). The report also includes information on Parkinson's Disease market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts. 

Scope
  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of KW 6002 including sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of KW 6002 including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2013-2020 for KW 6002 in Japan
Reasons to buy
  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
Table of Content

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3

2 Introduction 4
2.1 Parkinsons Disease 4
2.2 Symptoms of Parkinsons Disease 4
2.3 Diagnosis of Parkinsons disease 5
2.4 Parkinsons Disease Treatment Strategies 5
2.5 Parkinsons Disease Market 6
2.6 Epidemiology 6
2.7 Parkinsons Disease by Age and Gender 6
2.8 Etiology 7
2.9 GlobalData Report Guidance 7

3 Parkinsons Disease: Market Characterization 8
3.1 Parkinsons Disease Market 8
3.2 Parkinsons Disease Market Forecasts and CAGR 8
3.3 Factors Affecting Parkinsons Disease Market 9
3.3.1 High Prevalence: PD is the Second Most Frequent Neurodegenerative Disorder 9
3.3.2 Increase in Old Age Population 9
3.3.3 Patent Expiry of Prominent Drugs 9

4 Stages of Parkinsons Disease and Comparison of Treatments 10
4.1 The Hoehn and Yahr Scale 10
4.2 Modified Hoehn and Yahr Scale 10
4.3 The UPDRS 11

5 Staging of Parkinsons Disease 14
5.1 Distribution of Parkinsons disease Patients by Age Groups 14
5.2 Distribution of Patients by Stages 14

6 KW-6002 15
6.1 Introduction 15
6.2 Mechanism of Action 15
6.3 Clinical Studies 15
6.3.1 KW-6002 as monotherapy for Parkinsons disease 15
6.3.2 Efficacy and Safety of KW-6002 as an Add On to Levodopa in Patients with Advanced Parkinsons disease (Study 1) 15
6.3.3 Efficacy and Safety of KW-6002 as an Add On to Levodopa in Patients with Parkinsons disease (Study 2) 16
6.4 Factors Affecting Sales of KW-6002 16
6.4.1 First Mover Advantage 16
6.4.2 Low Efficacy Profile 16
6.4.3 Absence in the US and EU Market 17
6.4.4 Less Incidence of Dyskinesia 17
6.5 Drug Evaluation 17
6.5.1 Drug Risk Benefit Score 17
6.5.2 Intensity of Competition 18
6.6 Sales Forecasts 18
6.6.1 Target Patient Pool for KW-6002 18
6.6.2 Dosing 19
6.6.3 Market Penetration 19
6.6.4 Annual Cost of Therapy 20
6.6.5 Sales Projections of KW-6002 20

7 Parkinson Disease Market: Appendix 21
7.1 Market Definitions 21
7.2 List of Abberiviations 21
7.3 Research Methodology 21
7.3.1 Coverage 21
7.3.2 Secondary Research 22
7.3.3 Forecasting 22
7.3.4 Number of Patients Approved to take the Drug 22
7.3.5 Net Penetration of Drug 22
7.3.6 Net Annual Dosing 23
7.3.7 Annual Cost of Therapy 23
7.3.8 Primary Research 24
7.3.9 Expert Panels 24
7.4 Drug Sales Estimates Model 24
7.5 Contact Us 24
7.6 Disclaimer 24
7.7 Sources 25

List of Table


Table 1: Clinical Motor and Nonmotor Features of Parkinsons Disease 4
Table 2: Hoehn and Yahr Stages of Parkinsons Disease 10
Table 3: Hoehn and Yahr Stages of Parkinsons Disease 10
Table 4: Four Items, Part 1 of UPDRS 11
Table 5: Thirteen Items, Part 2 of Parkinsons disease 11
Table 6: Fourteen Items, Part 3 of UPDRS 12
Table 7: Fourteen Items, Part 3 of UPDRS 12
Table 8: Distribution of Parkinsons patients according to Hoehn and Yahr Classification 14
Table 9: Drug Risk Benefit Score of KW-6002 17
Table 10: KW-6002, Parkinsons Disease, Japan, Sales Forecasts ($m), 2013-2020 20

List of Chart


Figure 1: Current Pharmacologic Therapies for Parkinsons disease and Their Potential Sites of Action in the CNS 5
Figure 2: The Age-Specific Prevalence Rates of Parkinsons Disease in the Elderly Among Five European Countries, 2003 6
Figure 3: Parkinsons Disease, Global, Market Size Estimates ($bn), 20102020 8
Figure 4: Proportion of Population 60 Years or Older, World, 1950-2050 9
Figure 5: Points Distribution of UPDRS 13
Figure 6: Distribution of Parkinsons patients by Hoehn & Yahr Classification 14
Figure 7: Drug Model Diagram of KW-6002 in Japan 19
Figure 8: KW-6002, Parkinsons Disease, Japan, Sales Forecasts ($m), 2013-2020 20
Figure 9: Drug Model Diagram 23
Figure 10: Patients Approved for the Drug 23

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *